Skip to main content

Week in Review: China Life Science Scores over $1 Billion in Week's Deals

Deals and Financings   BGI Genomics of Shenzhen raised $300 million in a private placement for its next-gen sequencing services and clinical genetic tests; New Horizon Health staged a $263 million IPO in Hong Kong to support its early cancer screening tests, tripling in initial trading; Clover Biopharma of Chengdu closed a $230 million Series C round for its protein-based vaccines and cancer therapies, including a COVID-19 vaccine; Beijing 's YishengBio completed a $130 million Series B to develop immunomodulating biotherapeutics based on its novel PIKA® technology; ABclonal Biotechnology, a Massachusetts life science tools and services company, raised $93 million in a Series C financing led by China investors; Cullgen, a San Diego-Shanghai small molecule company, closed a $50 million Series B financing to support its targeted protein degradation candidates; AnchorDx Medical of Guangzhou completed a $40 million Series C financing for its cancer screening and early detection diagnostics; Bioelectronica, a Nevada company, raised $16 million in a Series A investment from China investors to support its novel drug discovery/development platform; COVID-19 Pandemic   Tianjin CanSino Biologics filed for China approval of its Ad5-nCoV COVID-19 vaccine that was 65% effective at preventing symptomatic COVID-19; Trials and Approvals   Junshi Bio's anti-PD-1, toripalimab, was approved in China as a first-line treatment for nasopharyngeal carcinoma, its second approved indication; I-Mab of Shanghai dosed the first patient in a pivotal China Phase III trial of a weekly treatment for pediatric growth hormone deficiency; Harbour BioMed was approved to start a China trial of its next-gen anti-CTLA-4 antibody in patients with advanced NSCLC and other solid tumors; Suzhou 's Innovent and IASO, a Bay Area-Nanjing biopharma, announced their partnered CAR-T candidate was granted Breakthrough status in China .  Stock Symbols: (SHZ: 300676) (HK: 6606) (HK: 6185; SHA: 688185) (HK: 1877; SHA: 688180) (NSDQ: IMAB) (HK: 02142) (HK: 01801) Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.